Nelson Capital Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Nelson Capital Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-325	Closed	-$13K	–	360
2017 Q3	$13K	Hold	325	–	–	﹤0.01%	200
2017 Q2	$10K	Hold	325	–	–	﹤0.01%	212
2017 Q1	$12K	Hold	325	–	–	﹤0.01%	207
2016 Q4	$16K	Hold	325	–	–	0.01%	198
2016 Q3	$17K	Hold	325	–	–	0.01%	192
2016 Q2	$13K	Hold	325	–	–	﹤0.01%	200
2016 Q1	$13K	Buy	+325	New	+$11.2K	﹤0.01%	189
2015 Q4	–	Sell	-325	Closed	-$5K	–	277
2015 Q3	$5K	Hold	325	–	–	﹤0.01%	233
2015 Q2	$8K	Buy	+325	New	+$7.24K	﹤0.01%	214

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Nelson Capital Management's FPRX Position: Q4 2017 in Review

Nelson Capital Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2017, closing a stake of 325 shares — an estimated $13K sold.

Nelson Capital Management first reported a position in FPRX in Q2 2015 and held it in 9 quarters. The position peaked at $17K in Q3 2016. 137 funds tracked by Wall St. Rank hold FPRX as of Q4 2017.

Nelson Capital Management reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Nelson Capital Management sold 325 Five Prime Therapeutics, Inc. shares in Q4 2017, an estimated $13K.
Nelson Capital Management first reported a position in Five Prime Therapeutics, Inc. in Q2 2015 and held it in 9 quarters.
Nelson Capital Management's Five Prime Therapeutics, Inc. position peaked at $17K in Q3 2016.
137 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2017.

Based on Nelson Capital Management's 13F filing for Q4 2017, filed 26 Jan 2018.